The Transformative Impact of Artificial Intelligence (AI) Models on Drug Discovery

Integrating artificial intelligence (AI) into healthcare is transforming drug discovery and development by addressing the inefficiencies of traditional methods, which can cost over $۱ billion and take more than a decade to produce results. Traditional approaches often face high failure rates and labor-intensive processes, causing delays in new therapies. Advanced deep learning models, such as Generative Adversarial Networks (GANs) and Graph Neural Networks (GNNs), significantly enhance drug discovery. GANs create novel chemical compounds from existing data, while GNNs improve predictions of drug-target interactions. Reinforcement Learning (RL) optimizes drug design by maximizing desired properties, and Recurrent Neural Networks (RNNs) enhance predictions of drug behavior in living organisms. Convolutional Neural Networks (CNNs) analyze biological images to identify potential drug candidates. AI-driven methods facilitate the rapid analysis of large datasets, expediting drug discovery amidst emerging diseases and complex biological systems. By overcoming traditional inefficiencies, these technologies can redefine pharmaceutical research, leading to more effective therapies and improved patient outcomes.

کلیدواژه ها:

Artificial Intelligence ، Drug Discovery ، Deep Learning